Determine if a cystatin C-inclusive vancomycin dosing algorithm improved target trough achievement compared to creatinine clearance-guided vancomycin therapy in critically ill patients.
This is a prospective, quality improvement study that evaluated critically ill patients initiated on intravenous vancomycin. Between January 2012 through October 2013, vancomycin was dosed at 15-20mg/kg at an interval guided by creatinine clearance using the Cockcroft Gault equation (control arm). Steady state trough concentrations were assessed prior to the 4th dose of a consistent regimen and compared to the individualized target trough range (10-15mg/L or 15-20mg/L) appropriate for the suspected or documented source of infection. Given low overall trough achievement observed with standard care, a quality improvement project was undertaken. After approval by local clinical practice committees with representation from the Division of Infectious Diseases, Pharmacy and Critical Care, a quality improvement project was undertaken to implement a new vancomycin dosing nomogram with dosing intervals based on the Chronic Kidney Disease Epidemiology Collaborative (CKD-EPI) creatinine-cystatin GFR equation, expressed in mL/min. After structured education was provided, the dosing algorithm was rolled out from December 2013 through May 2015 (intervention arm). Steady state target vancomycin trough achievement was compared between study arms with and without adjustment for potential confounders.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
399
Intravenous
Expressed in milliliters per minute
Vancomycin dosing algorithm based on creatinine clearance, expressed in milliliters per minute
Vancomycin target trough achievement
The percentage of initial steady state troughs within the target range.
Time frame: Baseline
Length of stay (hospital and ICU)
Time frame: Baseline
Acute kidney injury (AKI) and renal replacement therapy
New onset AKI, defined as KDIGO stage II or greater AKI, within 48-hours of and within 7-days of vancomycin initiation
Time frame: 7-days
Treatment failure
Treatment failure in patients with confirmed gram-positive infection after at least 48-hours of vancomycin therapy and within 7-days
Time frame: 7-days
Infection recurrence
New onset of infection within 28-days among patients with confirmed gram-positive infection
Time frame: 28-days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.